首页> 美国卫生研究院文献>Frontiers in Pharmacology >Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
【2h】

Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke

机译:丹红注射液联合t-PA改善局灶性栓塞性卒中的溶栓治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Hemorrhagic transformation, neurotoxicity, short treatment time windows, and other defects are considered as the major limitations for the thrombolytic therapy. This study is devoted to figure out whether Danhong injection (DHI) combined with tissue-plasminogen activator (t-PA) could extend the treatment time windows and ameliorate brain injury, hemorrhagic complication and BBB disruption after focal embolic stroke.Methods: In vitro, the combined concentrations of DHI and t-PA were added to wells reacted with plasminogen and D-Val-Leu-Lys-AMC. The optimum ratio of the combination of DHI plus t-PA was explored by detecting relative fluorescent. In vivo experiments, we firstly investigated the optimal dose of t-PA and Danhong injection for focal embolic stroke. The neurological deficit score, infarct volume and brain edema were assessed. Secondly, we proved that the combination group extended the thrombolytic window for treatment of focal embolic stroke. The neurological deficit score, infarct volume, brain edema and hemorrhagic complication were assessed, while levels of BAX, Bcl-2 and caspase-3 in brain tissue were analyzed by real-time polymerase chain reaction. Finally, to ask whether combination therapy with DHI plus t-PA protected the blood–brain barrier in a rat model of focal embolic stroke, neurological deficit score, ELISA, RT-PCR, western blot and fluorescence were used to detect the indicators of blood–brain barrier, such as tight junction protein, blood–brain barrier permeability and related gene expression.Results: In vitro, plasmin activity assays showed that the combination of t-PA with DHI at about 1:1.6 w/v ratio increased by almost 1.4-fold the plasmin-generating capability of t-PA. In vivo experiments, the results showed that the combination of Danhong injection (4 mL/kg) and t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h. And the combination t-PA (2.5 mg/kg) with DHI (4 mL/kg) ameliorated neurological score, cerebral infarction, brain edema, brain hemorrhage, and BBB disruption.Conclusion: Combination therapy with Danhong injection (4 mL/kg) plus t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h, ameliorate BBB disruption, reduce infarction, brain swelling and hemorrhage after ischemic stroke.
机译:背景:出血性转化,神经毒性,治疗时间窗短和其他缺陷被认为是溶栓治疗的主要局限性。这项研究致力于弄清楚丹红注射液(DHI)与组织纤溶酶原激活剂(t-PA)的结合是否可以延长治疗时间窗并改善局灶性栓塞性中风后的脑损伤,出血并发症和BBB破坏。方法: 在体外,将DHI和t-PA的合并浓度添加到与纤溶酶原和D-Val-Leu-Lys-AMC反应的孔中。通过检测相对荧光来探索DHI与t-PA结合的最佳比例。在体内实验中,我们首先研究了t-PA和丹红注射液治疗局灶性栓塞性中风的最佳剂量。评估神经功能缺损评分,梗塞体积和脑水肿。其次,我们证明了联合治疗组扩大了溶栓治疗窗,以治疗局灶性栓塞性中风。评估神经功能缺损评分,梗塞体积,脑水肿和出血并发症,同时通过实时聚合酶链反应分析脑组织中BAX,Bcl-2和caspase-3的水平。最后,要问DHI加t-PA的联合治疗是否能在局灶性栓塞性中风模型中保护血脑屏障,采用神经功能缺损评分,ELISA,RT-PCR,western blot和荧光检测血液指标-脑屏障,例如紧密连接蛋白,血脑屏障通透性和相关基因的表达。结果:在体外,纤溶酶活性测定表明t-PA与DHI的结合比例约为1:1.6 w / v比几乎增加了t-PA纤溶酶生成能力的1.4倍。在体内实验中,结果表明丹红注射液(4 mL / kg)和t-PA(2.5 mg / kg)的组合可将t-PA治疗时间窗延长至4.5 h。 t-PA(2.5 mg / kg)与DHI(4 mL / kg)的联合使用可改善神经系统评分,脑梗塞,脑水肿,脑出血和BBB破坏。结论:丹红联合治疗注射(4 mL / kg)加t-PA(2.5 mg / kg)可以将t-PA治疗时间窗延长至4.5 h,改善BBB破坏,减少缺血性卒中后的梗塞,脑肿胀和出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号